Loading
Tests whether a two-armed antibody against EGFR and a stem-cell marker can lift first-line immunotherapy results in head and neck cancer.
Phase 2 petosemtamab + pembrolizumab reported ORR ~63% in first-line PD-L1-positive HNSCC (ASCO 2025), far above pembrolizumab's historical ~19-23%. LiGeR-HN1 (first line, includes HPV-positive disease) and LiGeR-HN2 (second line, monotherapy vs chemotherapy) are the registrational trials; interim analyses expected 2026-27.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Petosemtamab, Genmab, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies.
Shares EGFR-directed bispecific + PD-1 blockade, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, EGFR.
Shares Petosemtamab, Genmab, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares EGFR-directed bispecific + PD-1 blockade, Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, EGFR.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Bispecific antibodies, Head and neck squamous cell carcinoma, Pembrolizumab.
Shares Petosemtamab, Genmab, Bispecific antibodies.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/